Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA402 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Dose escalation/de-escalation (Phase Ia) | EXPERIMENTAL | Dose-Finding of IMA402 as monotherapy or in combination with checkpoint inhibitor (Phase Ia) |
| Dose extension (Phase Ib) | EXPERIMENTAL | Extension cohorts of IMA402 as monotherapy or in combination based on maximum tolerated dose (MTD) and/or recommended doses for extensions (RDEs) (Phase Ib) |
| Dose extension (Phase II) | EXPERIMENTAL | Selected ISEC investigated on MTD/RDEs based on a manageable/favorable safety profile and initial signs of anti-tumor activity (Phase II) |
| Name | Type | Description |
|---|---|---|
| IMA402 | DRUG | IV infusions |
| IMA402 and checkpoint inhibitor | DRUG | IMA402 IV infusions and checkpoint inhibitor |
| IMA402 and chemotherapy | DRUG | IMA402 IV infusions and chemotherapy |
| IMA402 and IMA401 | DRUG | IMA402 and IMA401 IV infusions |
| IMA402 and monoclonal antibody | DRUG | IMA402 IV infusions and monoclonal antibody |
| IMA402 and chemotherapy +/- monoclonal antibody | DRUG | IMA402 IV infusions and chemotherapy +/- monoclonal antibody |
Inclusion Criteria: * Patients ≥ 18 years old * Patients must have a specific pathologically confirmed and documented advanced and/or metastatic solid tumor indication * Patients must have received or not be eligible for indicated standard-of-care treatments per cohort * Measurable disease accordin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
IMA402 is an investigational T cell-engaging receptor molecule (TCER) being developed for the treatment of refractory cancer, recurrent cancer, and solid tumors in adults. It is currently in Phase 1 clinical development for these oncology indications.
IMA402 targets PRAME, a tumor-associated antigen. It is designed as a T cell-engaging receptor molecule (TCER) to direct T cells against PRAME-expressing tumor cells. The drug is being studied in patients with recurrent and/or refractory solid tumors.
IMA402 is being developed by Immatics N.V., a biopharmaceutical company. Immatics is publicly traded under the ticker symbol IMTX. The company is conducting clinical trials of IMA402 in Germany and the Netherlands.
IMA402 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants with recurrent and/or refractory solid tumors.
IMA402 is being studied in a Phase 1 clinical trial with the identifier NCT05958121. This trial is titled 'IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors' and is currently recruiting participants in Germany and the Netherlands.
IMA402 is a T cell-engaging receptor molecule, also referred to as a TCER. It is designed to engage T cells to target PRAME-expressing tumor cells. The ongoing clinical trial specifically evaluates IMA402 as a TCER in patients with recurrent and/or refractory solid tumors.